Toby Maher
@TobyMMaher
Followers
3K
Following
586
Media
32
Statuses
721
Director of ILD @KeckMedUSC. @asthmalunguk Prof of Respiratory Research, @imperialNHLI Prof of Interstitial Lung Disease and #IPF doctor. Working to #cureIPF
Los Angeles, CA
Joined March 2012
RT @drphilmol: Fantastic news for all our patients with IPF who suffer with cough! An overall 43% reduction in cough counts, similar improv….
0
10
0
RT @KaminskiMed: When it rains it pours!! What an amazing #ATS2025 for #CurePF4ALL! Nerandomilast -> ⬇️FVC decline compared to placebo….
0
19
0
RT @KaminskiMed: Wow! What a day for #CureIPF & #ATS2025! First positive drug trial in 10 years in IPF!! Treatment with Nerandomilast -> ⬇️….
0
33
0
Great to see publication of the first positive phase 3 trial in patients with IPF. This represents an important step forward in the treatment of this terrible disease. #cureipf.
Presented at #ATS2025: . In the FIBRONEER-IPF phase 3 trial, nerandomilast slowed disease progression in patients with idiopathic pulmonary fibrosis as compared with placebo. Full trial results: . @atscommunity
2
14
46
RT @StradosLabs: A reminder to tune in to our session at #ATS2025 on cough in pulmonary fibrosis. Join @TobyMMaher to discuss how new techn….
0
1
0
RT @RespirologyAPSR: #ArtificialIntelligence and the Diagnosis of #InterstitialLungDisease: Are We Ready for ChatMDT?! ..
0
6
0
RT @StradosLabs: Join Strados Labs and @TobyMMaher at #ATS2025 for an engaging session on the often-overlooked symptom of cough in pulmonar….
0
2
0
RT @RespirologyAPSR: Predicting Failure: Can Blood Biomarkers Identify Likely Treatment Non-Responders in IPF? ..an….
0
1
0
RT @NatRevDrugDisc: Fibrosis: cross-organ biology and pathways to development of innovative drugs This new Review….
0
60
0
RT @RCPhysicians: Join us for the next episode in the specialty series on Tuesday 18 February at 6.30pm!. Our panel @R_tattersall, @Sarah_L….
0
3
0
RT @JAMA_current: @LRSorce @SebastianPalmqv @NiklasMattsson4 @criticcaredoc Most Viewed JAMA 2024: Interstitial Lung Disease.🔗 https://t.co….
0
5
0
RT @sclerodermaUM: Happy holidays everyone! We are late this year but here is the link to the 5th international symposium on ILDs in rheuma….
0
18
0
RT @PureTechH: We are thrilled to share positive topline data from our ELEVATE IPF Phase 2b trial evaluating deupirfenidone (LYT-100) for t….
0
5
0
RT @HealioPulm: ❗Patients with idiopathic pulmonary fibrosis (#IPF) had less #FVC decline between baseline and 26 weeks with receipt of thr….
0
2
0
RT @KaminskiMed: Wow! Boehringer-Ingelheim announces that Nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study -….
0
32
0
RT @ATSBlueEditor: Thanks to Tom McLellan, BA, MA, MRCP, for his contribution to the August 15 issue. Deep Learning–based Segmentation of C….
0
6
0
RT @KaminskiMed: I guess that's a sign of success - the day after I posted that the #ILDImmuneCellAtals was up - the website crushed becaus….
0
3
0
RT @adbyrne: Type 1 Invariant Natural Killer T Cells Drive Lung Fibrosis. Our latest work in press now @ATSBlueEditor Great collaborative p….
0
4
0
RT @KaminskiMed: Congratulations Dr. Selman for #ATS2024 Amberson Award! I wish could be there - but will cheer from New Haven!! And yes, y….
0
9
0
RT @ATSCPAssembly: An ILD Mini Symposium you won't want to miss!.👉Towards Implementation: New Biomarkers in ILD.⏰ May 19, 9:15-11:15AM.📍Mar….
0
5
0